Analyst Price Targets — BBNX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 18, 2026 1:42 pm | — | Lake Street | $20.00 | $12.45 | TheFly | Beta Bionics price target lowered to $20 from $40 at Lake Street |
| February 18, 2026 12:47 pm | — | Robert W. Baird | $14.00 | $13.97 | TheFly | Beta Bionics price target lowered to $14 from $28 at Baird |
| February 18, 2026 11:47 am | Jonathan Block | Stifel Nicolaus | $22.00 | $13.97 | TheFly | Beta Bionics price target lowered to $22 from $25 at Stifel |
| February 8, 2026 9:13 pm | — | UBS | $24.00 | $13.08 | TheFly | Beta Bionics initiated with a Buy at UBS |
| February 4, 2026 1:09 pm | — | Stifel Nicolaus | $25.00 | $14.06 | TheFly | Beta Bionics price target lowered to $25 from $31 at Stifel |
| February 2, 2026 2:54 pm | — | Truist Financial | $25.00 | $13.90 | TheFly | Beta Bionics price target lowered to $25 from $37 at Truist |
| January 26, 2026 9:41 pm | — | Cowen & Co. | $17.00 | $15.46 | TheFly | Beta Bionics initiated with a Hold at TD Cowen |
| January 15, 2026 11:33 am | David Roman | Goldman Sachs | $25.00 | $16.99 | TheFly | Beta Bionics price target lowered to $25 from $33 at Goldman Sachs |
| January 9, 2026 1:46 pm | — | Lake Street | $40.00 | $21.26 | TheFly | Beta Bionics price target raised to $40 from $35 at Lake Street |
| December 18, 2025 2:09 pm | Richard Newitter | Truist Financial | $37.00 | $30.45 | TheFly | Beta Bionics price target raised to $37 from $32 at Truist |
Latest News for BBNX
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their Options If you suffered significant losses in Beta Bionics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may…
Beta Bionics shares fell over 35% in January. Block & Leviton is investigating BBNX for possible securities laws violations. Investors may recover losses.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their Options If you suffered significant losses in Beta Bionics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click…
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their Options If you suffered significant losses in Beta Bionics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click…
NEW YORK, Feb. 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BBNX.
U.S. House Trading
No House trades found for BBNX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.